Preferred Label : satralizumab;
CISMeF synonym : satralizumab-mwge;
UNII : YB18NF020M;
Origin ID : C000655944;
UMLS CUI : C4726732;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3316324/fr/enspryng-satralizumab
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
satralizumab
injections, subcutaneous
neuromyelitis optica
adult
adolescent
Anti-aquaporin 4 antibody positivity
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
immunosuppressive agents
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
recurrence
drug therapy, combination
evaluation of the transparency committee
satralizumab
---
https://ansm.sante.fr/tableau-marr/satralizumab
2022
false
false
false
France
French
risk management
satralizumab
drug information
patient education handout
Interleukin Inhibitors
satralizumab
injections, subcutaneous
Infections
---
https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
satralizumab
satralizumab
drug approval
europe
satralizumab
adolescent
adult
aged
neuromyelitis optica
drug therapy, combination
orphan drug production
injections, subcutaneous
receptors, interleukin-6
drug monitoring
immunosuppressive agents
drug interactions
pregnancy
breast feeding
Interleukin Inhibitor
aquaporin 4
drug evaluation, preclinical
Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
neuromyelitis optica spectrum disorders who are anti-aquaporin 4 antibody positive
Anti-aquaporin 4 antibody positivity
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
